Alliance HealthCare Services
Irvine, CA | www.alliancemedical.com
Alliance HealthCare Services is a leading national provider of outsourced medical services including radiology, oncology, and interventional.
Healthcare and
Life Sciences
Our Approach
Strategic Capital and Tailored Solutions
Our team of seasoned healthcare investors provides strategic and often non-dilutive capital tailored to healthcare and pharma business timelines, whether to develop or launch new medicines, acquire assets, or provide growth capital to finance strategic initiatives.
Long-Term Partnerships
We are passionate about forming long-term partnerships with companies creating new technologies to address our most pressing healthcare challenges and improve patient care. Our experienced life sciences and technology teams focus on collaborating to develop AI and software-related themes within the healthcare space.
Broad Sector Expertise
We invest across the sector and have partnered with companies in drug development and marketing, devices and diagnostics, generics, pharma and healthcare business services, and contract research, development and manufacturing.
Healthcare IT and Software
Healthcare Data and AI
OTC, Consumer, Cosmeceuticals
Pharma Services, CROs, CDMOs, Life Science Tools
Medical Devices
Diagnostics
Pharmaceuticals and Biotechnology
Consumer Services
HEALTHCARE and LIFE SCIENCES
Our Solutions
Growth Equity
Working with both private and public companies, our custom financing solutions include and often combine common equity, convertible preferred equity, redeemable preferred equity, or convertible debt.
Direct Lending
We seek to work with companies about to commence commercial operations through to profitability with secured debt or debt-like financing. We can tailor terms and structure to reflect a company’s stage of growth.
Royalty Financing
Our team can work with companies on either passive royalty financings (company receives a passive third-party and typically non-dilutive royalty) or synthetic royalty financings (company creates royalty on its own product). Royalty financings can include traditional royalty purchases, structured royalty acquisitions (including annual or cumulative caps), or royalty-backed debt.
Clinical Trial Financing
We can work directly with companies to help bring new products or therapies to the market. Our structures can help companies achieve their financial, accounting, and strategic aims all while retaining control of the development of their assets.
Healthcare Fund Financing
We have worked directly with healthcare funds to help fund the exit of assets at the end of fund life, acquire earnouts, or help fund incremental investments post-LP commitment period. We can transact at the fund or asset level.
SELECT INVESTMENTS
Beginning in August 2020, Sixth Street provided $750 million in non-dilutive financing to support the commercial launch of or NURTEC ODT, the first FDA-approved oral medicine for the prevention and treatment of migraines. On May 10, 2022, Pfizer announced its acquisition of Biohaven for $11.6 billion.
Learn More SELECT INVESTMENTS
In 2021, Sixth Street made a strategic equity investment in Datavant concurrent with its merger with CIOX Health, a portfolio company of New Mountain Capital.
Learn More SELECT INVESTMENTS
Since first investing in 2018, Sixth Street has invested over $450 million of growth equity and debt capital in Caris Life Sciences, a leading innovator in molecular science developing the next generation of precision oncology profiling.
Learn More SELECT INVESTMENTS
In 2020, Sixth Street invested in MDLIVE, one of the fastest growing telehealth companies in the United States. MDLIVE was acquired by Cigna’s Evernorth in 2021.
Learn More SELECT INVESTMENTS
In September 2021, Sixth Street invested in the Series D for Mammoth Biosciences, a biotech company co-founded by Nobel laureate Jennifer Doudna that is building the next generation of CRISPR products in therapeutics and diagnostics.
Listen:
Janice Chen of Mammoth Biosciences speaks with David Stiepleman on Sixth Street’s It’s Not Magic podcast
Reproduced with permission from Bloomberg L.P.
Chief Science Advisor
We welcomed Jennifer Doudna, Ph.D., Nobel laureate and co-discoverer of CRISPR, as our Chief Science Advisor in February 2022 . Dr. Doudna assists Sixth Street in our long-term efforts to identify, evaluate, and advance commercial development opportunities within the CRISPR and gene-editing ecosystem. She is also leading the build of our Scientific Advisory Board, which will advise our team as we continue to finance the development and commercialization of innovative therapeutics and invest in healthcare technology companies across all stages of growth.
Learn MoreSIXTH STREET
Select Investments
